Application of Volumetric Analysis to Glioblastomas: a Correlation Study on the Status of the Isocitrate Dehydrogenase Mutation
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To investigate whether volumetric analysis based on T2WI and contrastenhanced(CE) T1WI can distinguish between isocitrate dehydrogenase-1 mutationpositive(IDH1P) and -negative (IDH1N) glioblastomas (GBMs). Materials and Methods: We retrospectively enrolled 109 patients with histopathologicallyproven GBMs after surgery or stereotactic biopsy and preoperative MR imaging. We measured the whole-tumor volume in each patient using a semiautomaticsegmentation method based on both T2WI and CE T1WI. We compared the tumorvolumes between IDH1P (n = 12) and IDH1N (n = 97) GBMs using an unpaired t-test. In addition, we performed receiver operating characteristic (ROC) analysis for thedifferentiation of IDH1P and IDH1N GBMs using the tumor volumes based on T2WIand CE T1WI. Results: The mean tumor volume based on T2WI was larger for IDH1P GBMs thanIDH1N GBMs (108.8 ± 68.1 and 59.3 ± 37.3 mm3, respectively, P = 0.0002). Inaddition, IDH1P GBMs had a larger tumor volume on CE T1WI than did IDH1N tumors(49.00 ± 40.14 and 22.53 ± 17.51 mm3, respectively, P < 0.0001). ROC analysisrevealed that the tumor volume based on T2WI could distinguish IDH1P from IDH1Nwith a cutoff value of 90.25 (P < 0.05): 7 of 12 IDH1P (58.3%) and 79 of 97 IDH1N(81.4%). Conclusion: Volumetric analysis of T2WI and CE T1WI could enable IDH1P GBMs tobe distinguished from IDH1N GBMs. We assumed that secondary GBMs with IDH1Punderwent stepwise progression and were more infiltrative than those with IDH1N,which might have resulted in the differences in tumor volume.
Abstract
Purpose: To investigate whether volumetric analysis based on T2WI and contrastenhanced(CE) T1WI can distinguish between isocitrate dehydrogenase-1 mutationpositive(IDH1P) and -negative (IDH1N) glioblastomas (GBMs). Materials and Methods: We retrospectively enrolled 109 patients with histopathologicallyproven GBMs after surgery or stereotactic biopsy and preoperative MR imaging. We measured the whole-tumor volume in each patient using a semiautomaticsegmentation method based on both T2WI and CE T1WI. We compared the tumorvolumes between IDH1P (n = 12) and IDH1N (n = 97) GBMs using an unpaired t-test. In addition, we performed receiver operating characteristic (ROC) analysis for thedifferentiation of IDH1P and IDH1N GBMs using the tumor volumes based on T2WIand CE T1WI. Results: The mean tumor volume based on T2WI was larger for IDH1P GBMs thanIDH1N GBMs (108.8 ± 68.1 and 59.3 ± 37.3 mm3, respectively, P = 0.0002). Inaddition, IDH1P GBMs had a larger tumor volume on CE T1WI than did IDH1N tumors(49.00 ± 40.14 and 22.53 ± 17.51 mm3, respectively, P < 0.0001). ROC analysisrevealed that the tumor volume based on T2WI could distinguish IDH1P from IDH1Nwith a cutoff value of 90.25 (P < 0.05): 7 of 12 IDH1P (58.3%) and 79 of 97 IDH1N(81.4%). Conclusion: Volumetric analysis of T2WI and CE T1WI could enable IDH1P GBMs tobe distinguished from IDH1N GBMs. We assumed that secondary GBMs with IDH1Punderwent stepwise progression and were more infiltrative than those with IDH1N,which might have resulted in the differences in tumor volume.
참고문헌 (23)
- Daumas-Duport C, "Grading of astrocytomas. A simple and reproducible method", Cancer, 62, pp.2152~2165 (1988)
- Pedersen CL, "Current treatment of low grade astrocytoma: a review", Clin Neurol Neurosurg, 115, pp.1~8 (2013)
- Balss J, "Analysis of the IDH1 codon 132 mutation in brain tumors", Acta Neuropathol, 116, pp.597~602 (2008)
- Nobusawa S, "IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas", Clin Cancer Res, 15, pp.6002~6007 (2009)
- Yan H, "IDH1 and IDH2 mutations in gliomas", N Engl J Med, 360, pp.765~773 (2009)
- Hartmann C, "Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas", Acta Neuropathol, 120, pp.707~718 (2010)
- Parsons DW, "An integrated genomic analysis of human glioblastoma multiforme", Science, 321, pp.1807~1812 (2008)
- Sanson M, "Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas", J Clin Oncol, 27, pp.4150~4154 (2009)
- Levner I, "Predicting MGMT methylation status of glioblastomas from MRI texture", Med Image Comput Comput Assist Interv, 12, pp.522~530 (2009)
- Jenkinson MD, "Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features", Brain, 129, pp.1884~1891 (2006)
- Aghi M, "Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma", Clin Cancer Res, 11, pp.8600~8605 (2005)
- Mut M, "Neuroimaging characteristics in subgroup of GBMs with p53 overexpression", J Neuroimaging, 17, pp.168~174 (2007)
- DeLong ER, "Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach", Biometrics, 44, pp.837~845 (1988)
- Lee S, "Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1", 2 gene mutation using histogram analysis of diffusionweighted imaging and dynamic-susceptibility contrast perfusion imaging, 2015, pp.121, 141~150
- Ohgaki H, "The definition of primary and secondary glioblastoma", Clin Cancer Res, 19, pp.764~772 (2013)
- Paganetti PA, "Glioblastoma infiltration into central nervous system tissue in vitro: involvement of a metalloprotease", J Cell Biol, 107, pp.2281~2291 (1988)
- Andronesi OC, "Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate", J Clin Invest, 123, pp.3659~3663 (2013)
- Pope WB, "Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy", J Neurooncol, 107, pp.197~205 (2012)
- Choi C, "2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDHmutated patients with gliomas", Nat Med, 18, pp.624~629 (2012)
- SongTao Q, "IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma", Cancer Sci, 103, pp.269~273 (2012)
- Tran AN, "Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry", Neuro Oncol, 16, pp.414~420 (2014)
- Carrillo JA, "Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma", AJNR Am J Neuroradiol, 33, pp.1349~1355 (2012)
- Jiao Y, "Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas", Oncotarget, 3, pp.709~722 (2012)